RxDoctor Payments DataLook up a doctor →

Burton Tabaac, MD

Neurology · Reno, NVNPI 1295154219

Payments from drug & device makers

$287,285in general payments, 2019–2025

Across 848 payments — averaging $338.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$90K
  • Otsuka America Pharmaceutical, Inc.$73K
  • AbbVie$51K
  • AstraZeneca$41K
  • Pfizer$24K
  • Neurocrine Biosciences, Inc.$865
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$1,5251%
  • Speaking & faculty fees$258,80590%
  • Travel & lodging$11,2854%
  • Food & beverage$15,5485%
  • Education$1220%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$287,285 in reported general payments places this provider in the 90th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$149,817
Medicare patients
427
Services billed
1,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine40$265,890
IngrezzaValbenazine Tosylate15$122,095
RytaryCarbidopa/Levodopa55$71,753
NuplazidPimavanserin Tartrate14$69,965
Aimovig AutoinjectorErenumab-Aooe93$66,882
EliquisApixaban65$61,560
UbrelvyUbrogepant39$52,270
Nurtec OdtRimegepant Sulfate31$49,660
BriviactBrivaracetam18$36,534
NeuproRotigotine28$31,239
GocovriAmantadine Hcl12$23,910
Repatha SureclickEvolocumab30$18,956
Emgality PenGalcanezumab-Gnlm28$18,896
BotoxOnabotulinumtoxina13$17,787
Lacosamide71$12,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$98$265,89040 claims
Neurocrine Biosciences, Inc.Ingrezza$865$122,09515 claims
PfizerEliquis, Nurtec Odt$24,176$111,22196 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$129$76,63999 claims
AbbVieUbrelvy, Botox$50,942$70,05752 claims
Acadia Pharmaceuticals IncNuplazid$36$69,96514 claims
UCB, Inc.Briviact, Neupro$618$67,77246 claims
MDD US Operations, LLCGocovri$36$23,91012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 145 neurology providers in Nevada.

Other neurology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →